Pevonedistat (MLN4924) is a selective NEDD8 inhibitor. [1] It is being investigated as a cancer treatment, e.g. for mantle cell lymphoma (MCL). [1]

2017年7月17日 · MLN4924 is a neddylation inhibitor currently under investigation in multiple phase I studies on various malignancies, and its clincal name is Pevonedistat. It has been …

2020年7月21日 · Pevonedistat (MLN4924), a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit (NAE1), has demonstrated significant therapeutic potential in several …

2010年9月2日 · MLN4924 is a potent and selective small molecule NEDD8-activating enzyme (NAE) inhibitor. In most cancer cells tested, inhibition of NAE leads to induction of DNA …

MLN4924 is a first-in-class inhibitor of the proximal regulator of the NEDD8 system (NEDD8-activating enzyme, NAE) that has entered Phase-I trials for cancer therapy and has …

2017年7月17日 · It has been documented that MLN4924 blocks Cullins neddylation and inactivates CRLs and, in turn, triggers cell-cycle arrest, apoptosis, senescence and autophagy …

Pevonedistat (MLN4924) is a potent inhibitor of NAE, and is selective relative to the closely related enzymes UAE, SAE, UBA6 and ATG7 (IC 50 =1.5, 8.2, 1.8 and >10 μM, respectively) …

MLN4924 (Pevonedistat) is a potent and selective inhibitor of NEDD8-activating enzyme (NAE) (1). The NAE is part of the NEDD8 conjugation pathway that involves the ubiquitin-like NEDD8 …

2020年1月20日 · Here, we show that the NAE inhibitor, Pevonedistat (MLN4924), potently inhibits RB1null and MYCNamp tumors. Intravitreal MLN4924 suppressed multiple human xenografts …